via Wikipedia
Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.
In their findings (reported in The Lancet Infectious Diseases), they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
The authors report from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. A total of 450 participants aged five to 17 months were recruited from the catchment area of Nanoro, with 409 receiving the booster.
The participants were randomly assigned to three groups, with the first two groups receiving the R21/Matrix-M (with either a low dose or high dose of the Matrix-M adjuvant) vaccine as a booster and the third a rabies vaccine as the control group. Each child received the same booster vaccination as their primary series of vaccinations. Doses were administered in June 2020, largely prior to the peak malaria season.
The researchers report a vaccine efficacy of 80% in the higher-dose adjuvant group, and 70% in the lower dose adjuvant group, over 12 months of follow-up. Antibody levels were restored to similar levels as those following the primary vaccinations 28 days after the booster doses were administered. No serious adverse events related to the vaccine were noted.
Halidou Tinto, Professor in Parasitology, Regional Director of IRSS in Nanoro, and the trial Principal Investigator, said: ‘It is fantastic so see such high efficacy again after a single booster dose of vaccine. We are currently part of a very large phase III trial aimed at licensing this vaccine for widespread use next year.’
Professor Adrian Hill, the University of Oxford’s Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology, and co-author of the paper, said: ‘We are delighted to find that a standard four dose immunisation regime can now, for the first time, reach the high efficacy level over two years that has been an aspirational target for malaria vaccines for so many years.’
The R21/Matrix-M™ malaria vaccine candidate created by the University of Oxford includes Novavax’ proprietary saponin-based Matrix-M adjuvant and is licensed to Serum Institute of India.
The trial – funded by the EDCTP2 programme supported by the European Union (grant number RIA2016V-1649-MMVC) as well as the Wellcome Trust and NIHR Oxford Biomedical Research Centre – has been extended for another two years to assess if further booster doses will be necessary to maintain high efficacy over time.
Results from the key ongoing Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged five to 36 months across four African countries, are also expected later this year.
Gareth Jenkins, Director of Advocacy at Malaria No More UK said: ‘Today’s R21 vaccine results from Oxford’s renowned Jenner Institute are another encouraging signal that, with the right support, the world could end child deaths from malaria in our lifetimes.
‘But for new British inventions to achieve their potential, British leadership must continue, not least at the imminent US-hosted Global Fund to Fight AIDS, Tuberculosis and Malaria replenishment conference this September.
‘This will be the new PM’s first foreign policy test – for the sake of millions of children’s lives, global health security, and British relations with its closest ally, it’s a test they cannot fail.’
Original Article: Malaria booster vaccine shows durable high efficacy in African children, meeting WHO-specified 75% efficacy goal
More from: University of Oxford
The Latest Updates from Bing News
Go deeper with Bing News on:
Malaria vaccine
- mRNA malaria vaccine due for first clinical trial
Mahidol University has inched closer to starting the world's first clinical trial of an mRNA vaccine against malaria.Already tested on mice during a past laboratory trial, the vaccine candidate will ...
- Next-Gen malaria jabs can achieve WHO strategic goal
Almost half of the world’s population is at risk of malaria infection with some 249 million people diagnosed with the disease in 2022 ...
- Key Considerations: Effective Vaccine Rollout and Uptake in Sierra Leone
Sierra Leone received its first shipment of 550,000 malaria vaccines in December 2023, marking a milestone for public health in a country that sees over two million hospital visits for malaria ...
- Data arms Africa’s fight against malaria
In March, ministers of health from 11 countries with the highest malaria burden on the continent met in Yaoundé, Cameroon, and committed to accelerating malaria mortality reduction. They made a ...
- Malaria Vaccine: Why is it Taking so Long?
The RTS,S construct formulated with the adjuvant AS02 gave approximately 50% protection from clinical malaria in a Phase IIa trial. Field trials ensued with an efficacy of 30–60% in a 6–12 ...
Go deeper with Bing News on:
Malaria
- Tripura: Health department to launch door-to-door malaria surveillance in remote areas
Secretary of the Health Department, Tripura, Kiran Gitte, told ANI, "The health department of Tripura will soon start door-to-door surveillance for the detection of malaria in remote pockets of the ...
- Malaria cases dip, hosp strives to find patients for drug trial
Kolkata: The number of pre-monsoon malaria cases in the city has witnessed a sharp dip when compared to last year. According to a KMC health department source, the malaria clinics across 144 wards ...
- The harrowing tale of Patriots player Calvin Anderson’s near-fatal bout with malaria
Anderson’s body temperature spiked wildly in the early-morning hours of July 22. Sherée used Instacart to track down a thermometer. She stuck it in Calvin’s mouth, waking him up. After a minute, the ...
- Ethiopia Renews Fight Against Malaria on World Malaria Day
Jigjiga stadium hosted the main event, with high-level officials like Engineer Mohamed Shalle, Head of the Somali Region Prosperity Party, in attendance ...
- How Can We Prevent Malaria? A Review By Doctors
Expert opinion from Daniel A. Foster DO, MPH · 16 years of experience · USA To reduce your risks of contracting malaria, you should do the following: Apply DEET (diethyltoluamide) insect repellent to ...